After the FDA approved a Sage Therapeutics drug for postpartum depression but not major depression on Aug. 4, the company delayed announcing its list price and the CFO hinted that Sage is considering reducing its workforce and pipeline.
"We … are currently evaluating resource allocation, including pipeline prioritization and a workforce reorganization," CFO Kimi Iguchi said in an Aug. 7 investor call.
The drug, Zurzuvae (zuranolone), is the first FDA-approved drug to treat postpartum depression, but Sage and its partner Biogen have not yet announced the list price.
Sage did not immediately reply to Becker's request for details on how many jobs might be affected, and no WARN notices have been filed in states with Sage locations, Massachusetts and North Carolina.